Biotechnology News

SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints...

Mr Tyson has both clinical experience treating patients with serious mental health disorders and 25 years of successful industry commercial experience in the development and sales of medications in...

KUALA LUMPUR, Malaysia, April 13, 2026 (GLOBE NEWSWIRE) -- CUKTECH, peneraju global dalam penyelesaian kuasa pintar, hari ini mengumumkan pelancaran rasmi produk utamanya yang sangat dinantikan di...

KUALA LUMPUR, Malaysia, April 13, 2026 (GLOBE NEWSWIRE) -- CUKTECH, a global leader in intelligent power solutions, today announced the official Malaysian launch of its highly anticipated flagship:...

CAMBRIDGE, Royaume-Uni et MONTRÉAL, 13 avr. 2026 (GLOBE NEWSWIRE) -- Epitopea, une société transatlantique spécialisée dans l'immunothérapie contre le cancer qui développe des immunothérapies à...

CAMBRIDGE, United Kingdom and MONTREAL, April 13, 2026 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies...

KØBENHAVN, Danmark, 13. april 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggør transaktioner under aktietilbagekøbsprogrammet, der blev iværksat den 12. marts 2026, hvorunder selskabet vil...

COPENHAGEN, Denmark, April 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares...

BASEL, Switzerland, April 13, 2026 (GLOBE NEWSWIRE) -- BioVersys and partners publish in the prestigious journal of Nature Communications pre-clinical development data of AlpE (alpibectir and...

BioNTech today announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in HER2+ endometrial cancer.